Patents by Inventor Dhanapalan Nagarathnam

Dhanapalan Nagarathnam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
    Publication number: 20180000855
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 4, 2018
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • NOVEL COMPOUNDS AS MODULATORS OF GPR-119
    Publication number: 20170342089
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
    Patent number: 9815831
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 14, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Compounds as modulators of protein kinases
    Patent number: 9775841
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 3, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant Kashinath Bhavar
  • Compounds as modulators of GPR-119
    Patent number: 9777018
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 3, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20170204105
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Inventors: Swaroop Kumar V.S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Selective PI3K delta inhibitors
    Patent number: 9669033
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: June 6, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Nucleoside phosphoramidate prodrugs
    Patent number: 9585906
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: March 7, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael J. Sofia, Peiyuan Wang
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20170020881
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Swaroop Kumar V.S. VAKKALANKA, Meyyappan MUTHUPPALANIAPPAN, Dhanapalan NAGARATHNAM
  • Selective PI3K delta inhibitors
    Patent number: 9475818
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 25, 2016
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20150361083
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 17, 2015
    Inventors: Swaroop Kumar V.S. VAKKALANKA, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • NOVEL COMPOUNDS AS MODULATORS OF GPR-119
    Publication number: 20150361092
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 17, 2015
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES
    Publication number: 20150320752
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: June 25, 2015
    Publication date: November 12, 2015
    Inventors: Dhanapalan NAGARATHNAM, Swaroop K. VAKKALANKA, Meyyappan MUTHUPPALANIAPPAN, Srikant VISWANADHA, Govindarajulu BABU, Prashant K. BHAVAR
  • Bicyclic compounds as modulators of GPR-119
    Patent number: 9181214
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 10, 2015
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • Selective PI3K delta inhibitors
    Patent number: 9150579
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: October 6, 2015
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
    Publication number: 20150231166
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: March 12, 2015
    Publication date: August 20, 2015
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael J. Sofia, Peiyuan Wang
  • Nucleoside phosphoramidate prodrugs
    Patent number: 9085573
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: July 21, 2015
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC
    Publication number: 20150057309
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 26, 2015
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Nucleoside phosphoramidates
    Patent number: 8957045
    Abstract: A nucleoside compound having activity against hepatitis C virus is disclosed.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: February 17, 2015
    Assignee: Gilead Pharmasset LLC
    Inventors: Michael Joseph Sofia, Jinfa Du, Peiyuan Wang, Dhanapalan Nagarathnam
  • Nucleoside phosphoramidate prodrugs
    Patent number: 8957046
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: February 17, 2015
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang